Apeloa Pharmaceutical Co.,Ltd
000739
Rangering i aksjer
#4290
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Aksjekurs
$3.13
Markedsverdi
$3.62B
Endring (1 dag)
-1.42%
Endring (1 år)
46.59%
Land
CN
Handel Apeloa Pharmaceutical Co.,Ltd (000739)
Kategori
Healthcare
P/S-forhold for Apeloa Pharmaceutical Co.,Ltd (000739)
P/S-forhold per October 2026 TTM: 3.02
Ifølge Apeloa Pharmaceutical Co.,Ltd sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 3.02. Ved slutten av 2024 hadde selskapet et P/S-forhold på 1.57.
P/S-historikk for Apeloa Pharmaceutical Co.,Ltd fra 2000 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 3.02 | 57.19% |
| 2025 | 1.92 | 22.72% |
| 2024 | 1.57 | -0.75% |
| 2023 | 1.58 | -33.91% |
| 2022 | 2.39 | -48.35% |
| 2021 | 4.62 | 32.81% |
| 2020 | 3.48 | 64.26% |
| 2019 | 2.12 | 54.78% |
| 2018 | 1.37 | 1.75% |
| 2017 | 1.35 | -25.37% |
| 2016 | 1.80 | -16.80% |
| 2015 | 2.17 | 10.98% |
| 2014 | 1.95 | 89.77% |
| 2013 | 1.03 | 121.00% |
| 2012 | 0.47 | -61.20% |
| 2011 | 1.20 | -22.31% |
| 2010 | 1.55 | -17.73% |
| 2009 | 1.88 | 119.94% |
| 2008 | 0.85 | -67.41% |
| 2007 | 2.62 | 135.37% |
| 2006 | 1.11 | 99.43% |
| 2005 | 0.56 | -31.73% |
| 2004 | 0.82 | -9.78% |
| 2003 | 0.91 | -43.62% |
| 2002 | 1.61 | -86.69% |
| 2001 | 12.08 | 16.98% |
| 2000 | 10.33 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 133.86% |
IN
|
